Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy

Abstract

ObjectivesTo quantify the relationship between exposure to lacosamide monotherapy and seizure probability, and to simulate the effect of changing the dose regimen.MethodsStructural time-to-event models for dropouts (not because of a lack of efficacy) and seizures were developed using data from 883 adult patients newly diagnosed with epilepsy and experiencing focal or generalized tonic–clonic seizures, participating in a trial (SP0993; ClinicalTrials.gov identifier: NCT01243177) comparing the efficacy of lacosamide and carbamazepine controlled-release monotherapy. Lacosamide dropout and seizure models were used for simulating the effect of changing the initial target dose on seizure freedom.ResultsRepeated time-to-seizure data were described by a Weibull distribution with parameters estimated separately for the first and subsequent seizures. Daily area under the plasma concentration–time curve was related linearly to the log-hazard. Disease severity, expressed as the number of seizures during the 3 months before the trial (baseline), was a strong predictor of seizure probability: patients with 7–50 seizures at baseline had a 2.6-fold (90% confidence interval 2.01–3.31) higher risk of seizures compared with the reference two to six seizures. Simulations suggested that a 400-mg/day, rather than a 200-mg/day initial target dose for patients with seven or more seizures at baseline could potentially result in an additional 8% of seizure-free patients for 6 months at the last evaluated dose level. Patients receiving lacosamide had a slightly lower dropout risk compared with those receiving carbamazepine.ConclusionBaseline disease severity was the most important predictor of seizure probability. Simulations suggest that an initial target dose >200 mg/day could potentially benefit patients with greater disease severity.Electronic supplementary materialThe online version of this article (doi:10.1007/s40262-017-0530-8) contains supplementary material, which is available to authorized users.

Modelling ASthma TrEatment Responses (MASTER): Effect of individual patient characteristics on the risk of exacerbation in moderate or severe asthma: A time‐to‐event analysis of randomized clinical trials

“…This approach provides a parametric representation of the event rate (incidence) along with the underlying hazard. 21,22 In addition, the availability of such a TTE model will allow systematic evaluation of the effect of multiple contributing factors to the risk of exacerbation, disentangling drugspecific from patient-related effects. 23…”

“…More specifically, we aim to develop and evaluate the performance of a time‐to‐event (TTE) model describing the risk of exacerbation following administration of fluticasone propionate as monotherapy (FP) and in combination with salmeterol (FP/SAL), and budesonide‐formoterol combination therapy (BUD/FOR) to patients with moderate or severe asthma. This approach provides a parametric representation of the event rate (incidence) along with the underlying hazard 21,22 . In addition, the availability of such a TTE model will allow systematic evaluation of the effect of multiple contributing factors to the risk of exacerbation, disentangling drug‐specific from patient‐related effects 23 …”

Model‐based meta‐analysis of the time to first acute urinary retention or benign prostatic hyperplasia‐related surgery in patients with moderate or severe symptoms

“…This approach presents a parametric representation of the event rate (incidence) along with the underlying hazard. 10 , 11 In addition, the availability a TTE model also facilitates a systematic evaluation of the impact of multiple contributing factors to the risk of AUR/S, enabling accurate prediction of the effect of recommended interventions in patients with moderate or severe symptoms at risk of disease progression.…”